Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CORINTH Trial: Pembrolizumab plus chemoradiation in anal cancer
2024-515369-33-00Phase 2Authorised
- Sponsor
- Cardiff University
- Start
- Jan 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
Phase 2, open-label trial of pembrolizumab in anal squamous cell carcinoma (SCCA) (2 arms), sponsored by Cardiff University. Primary endpoint: Safety and tolerability of pembrolizumab plus standard CRT in two schedules. Planned start Jan 2025; status: authorised.
02
Drugs
03
Conditions
anal squamous cell carcinoma (SCCA)
Beyond the preview
Go deeper on 2024-515369-33-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515369-33-00.